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Abstract: Crude national ambulatory antibiotic dispensing data (2007–2011) of adult patients (aged between 20 and below
65 years) with CAP were obtained and expressed as DDD per 1000 inhabitants and per day (DID). European quality indicators
of antibiotic prescribing were calculated and adherence rate to the national CAP guideline was assessed. Antibiotic use for CAP
in adults ranged between 0.27 and 0.30 DID in various years. The most frequently used antibacterials were levofloxacin,
co-amoxiclav and clarithromycin. Antibiotic use in CAP was compliant with the European recommendations in 6.4% in 2007,
which decreased to 4.9% by 2011, in contrast to the optimal compliant range of 80–100%. The consumption of fluoroquinolones
mounted up to ~40% in both genders, which exceeded the recommended range (0–5%) substantially. National guideline also
favoured the use of macrolides in the empiric therapy of CAP in otherwise healthy adults; hence, guideline-concordant antibiotic
use ranged between 24.0–32.3%. Agents that were contra-indicated in the empiric therapy of CAP were also used in 6.5–9.0%
in various years. These data reflect some worrisome figures and trends in the outpatient antibiotic treatment of adults with CAP.
Clarified and updated national guidelines focusing on outpatients and incentives/regulations to increase guideline concordance
are warranted.
Community-acquired pneumonia (CAP) is a major health prob-
lem worldwide and is associated with considerable morbidity,
mortality and healthcare costs [1]. In 2012, lower respiratory
tract infections ranked the fourth most common cause of death
worldwide [2], while CAP itself is considered the most frequent
cause of infection-related death both in the Europe and in the
USA [3]. Also, an acute CAP episode per patient results in
25.5 days of absence from work on average [4].
Ambulatory care antibiotic treatment of CAP is basically
empiric everywhere [5,6] and should be guided by profes-
sional recommendations. National guidelines for the treatment
of CAP have been available for many years. Moreover, based
on the consensus of several national guidelines, disease-spe-
cific prescribing quality indicators were recently defined for
the most common indications of outpatient antibiotic use
including pneumonia [7].
The appropriateness of antibiotic use can be assessed by
adherence rate to the national guidelines and by comparison
with international prescribing quality indicators. The aim of
this study was to describe antibiotic treatment patterns of adult
outpatients with community-acquired pneumonia (CAP) in the
light of internationally developed disease-specific quality indi-
cators and national recommendations.
Materials and Methods
The crude data on systemic ambulatory antibiotic use were purchased
from the National Health Fund Administration (NHFA). According to
the age limitations of the international quality indicator and relevant
section of national CAP guideline, we included all antibiotic prescrip-
tions of adult patients (aged between 20 and below 65 years) claimed
between 2007 and 2011 in the analysis.
As NHFA is the only mandatory, health insurance fund in Hungary,
and antibiotics are almost exclusively reimbursed agents, this database
provides nearly 100% population and drug dispensation coverage.
Antibiotic use was evaluated by the anatomical therapeutic chemical
(ATC) classification and defined daily dose (DDD) measurement unit
(version 2012). Population data were derived from Eurostat.
The International Classification of Diseases (ICD) codes (version
10) are displayed on Hungarian prescriptions and captured in claims
data, which allow indication-specific assessment of antibiotic use.
The ESAC developed quality indicators pertained for the R-81 code
of the International Classification of Primary Care, second revision
(ICPC-2-R code). The conversion between the ICD-10 and the
ICPC-2-R codes was performed according to the prescribing quality
indicators report published on the website of the European Center for
Disease Prevention and Control [8].
ICD codes pertaining to pneumonia (J12, J13, J14, J15, J17, J18)
were included in the analysis. The ESAC 7a indicator represents
adult patients (18–65 years) with pneumonia (ICPC-2R: R81) receiv-
ing systemic antibacterial therapy (acceptable range: 90–100%). The
ESAC 7b indicator shows the percentage of 7a patients receiving the
recommended antibacterials (ATC: J01CA penicillins with extended
spectrum and J01AA: tetracyclines; acceptable range: 80–100%)
whereas 7c reflects the patients who received quinolones (ATC:
J01M, acceptable range: 0–5%). Calculation of the ESAC 7a indica-
tor was not feasible with our data set. The ESAC 7b disease-specific
quality indicator was estimated by the relative use of the ESAC-rec-
ommended antibacterial agents and ESAC 7c by the relative use of
quinolones. The results were compared to the pre-defined acceptable
ranges.
Adherence rate to the national CAP recommendation was also
assessed. The guideline – issued by the Hungarian Professional Col-
lege of Infectious Diseases and Pulmonology – has been published
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each year with unchanged content since 2006, and therefore, it was
valid for the whole study period [9].
The recommended empiric therapy in Group 1 patients (individuals
below the age of 65 years and without comorbidities) with CAP was
as follows:
1 Macrolide OR amoxicillin (min. 3 g daily) OR doxycycline without
any particular order.
2 Not recommended: penamecillin, penicillin V, ampicillin, cepha-
lexin, cefaclor, sulphamethoxazole/trimethoprim, second-generation
fluoroquinolones (e.g. ciprofloxacin, ofloxacin, pefloxacin), third-
generation oral cephalosporins (ceftibuten, cefixime)
3 Levofloxacin was recommended only in case of penicillin allergy or
if initial empiric therapy failed. (Co-amoxiclav was not mentioned
in this patient group; they were recommended only in patients with
comorbidities).
As our primary data pertained to adults (aged between 20 and
65 years), we estimated guideline concordance in this patient group
with the limitation that we could not exclude cases with comorbidities.
However, to quantify this limitation, prevalence rate of relevant com-
orbidities (chronic obstructive pulmonary disease, cystic fibrosis,
tuberculosis diabetes, renal failure) was retrieved from the database of
the Hungarian Central Statistical Office.
For data managing, we used MS Excel and R (version 3.1.2).
Results
For adults with CAP, the recorded antibiotic use ranged
between 0.27 and 0.30 DDD per 1000 inhabitants and per day
(DID) in various years, which corresponded to 2.25–2.65% of
total outpatient antibiotic use in Hungary. Oral antibiotics
were prescribed almost exclusively (98.8% in 2007 and 99.6%
in 2011). The use of the top ten agents at the two study end-
points is displayed in table 1.
Beta-lactam antibacterials headed the consumption list from
2007 to 2010, and their relative share was around 30% in each
year. Combinations of penicillins with beta-lactamase inhibi-
tors were the most prominent antibiotic subclass (representing
more than 90% of the penicillin group each year). The fluor-
oquinolones accounted for 25.6% of antibiotic use in adults
with CAP in 2007 which reached 40.4% by 2011. Levofloxa-
cin, moxifloxacin and ciprofloxacin were among the most
commonly used agents each year (table 1). In parallel, the rel-
ative use of macrolides gradually decreased from 26.3% in
2007 to 19.4% in 2011. Relative use of tetracyclines in CAP
ranged from 3.9 to 4.4% without identifiable trend.
No significant gender differences in the antibiotic choice
were observed.
Adherence rate to the Hungarian guideline is displayed in
fig. 1, while antibiotic use according to the ESAC defined dis-
ease-specific quality indicators is summarized in table 2.
Agents recommended as first-line therapy for adults (aged
18–65 years without certain comorbidities) in the national
guideline were used in 32.3% adults in 2007 and 24.3% in
2011. Agents that were discouraged to be used in the empiric
therapy of CAP (e.g. sulphamethoxazole/trimethoprim and
penamecillin, see complete list in the Methods section) were
used in 9% in 2007, which gradually decreased to 6.5% by 2011.
The use of the internationally recommended antibacterials
(quality indicator 7b) was 20 times lower than acceptable
range (4.9–6.4% versus the optimal 80–100%) and showed a
downward trend in both genders (table 2). In parallel, the
gradual increase in fluoroquinolones use (quality indicator 7c)
was observed in both genders, and in 2011, their use exceeded
the ESAC-recommended limit more than eight times (table 2).
Discussion
According to recent European antibiotic surveillance data,
Hungarian ambulatory care antibiotic use ranks among the
lowest consumers in the northern European countries, while
the pattern of use resembles that of southern European coun-
tries [10,11]. Therefore, studies revealing the treatment pattern
of certain infections are important.
Although up to 80% of the treatment of CAP is provided in
the outpatient setting [12], only very few recent studies have
addressed the management of outpatients [4,13–18]. Some of
these studies [13,17] focused only on specific cases (i.e.
patients showing up in emergency wards), and with the excep-
tion of two papers [4,18], they pertain to USA or Canada.
To overcome this scarcity, we hereby report and evaluate the
patterns and trends of CAP treatment in Hungarian ambulatory
care.
The quality of antibiotic use in pneumonia – by comparing
with disease-specific quality indicators – has been evaluated
by only one study so far [18]. The usage rate of recommended
antibacterials in CAP was higher in their study (25% on aver-
Table 1.
Use of the top ten antibacterials in adults with
community-acquired pneumonia.
2007 2011
ATC Active agent DID % ATC Active agent DID %
1 J01CR02 Co-amoxiclav 0.08 29.63 J01MA12 Levofloxacin 0.09 29.04
2 J01FA09 Clarithromycin 0.05 18.61 J01CR02 Co-amoxiclav 0.08 25.28
3 J01MA12 Levofloxacin 0.04 12.89 J01FA09 Clarithromycin 0.04 12.86
4 J01MA14 Moxifloxacin 0.02 8.67 J01MA14 Moxifloxacin 0.02 7.78
5 J01FA10 Azithromycin 0.02 6.36 J01FA10 Azithromycin 0.02 6.55
6 J01DC02 Cefuroxime 0.01 5.08 J01DC02 Cefuroxime 0.02 5.51
7 J01AA02 Doxycycline 0.01 4.28 J01AA02 Doxycycline 0.01 4.15
8 J01MA02 Ciprofloxacin 0.01 3.72 J01MA02 Ciprofloxacin 0.01 3.30
9 J01CA04 Amoxicillin 0.00 1.71 J01DD08 Cefixime 0.00 1.39
10 J01DD14 Ceftibuten 0.00 1.67 J01DD14 Ceftibuten 0.00 0.95
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age versus around 5% in our study), while their proportional
quinolone use was similar [18].
National guideline-concordant antibiotic use varied greatly
in the literature. In a recent Spanish outpatient study, treatment
of bronchitis conformed to national guideline in 17%, [19]
while a previous study focusing on CAP recorded 51.1%
guideline adherence [4]. Mean guideline adherence rate in a
US CAP study was 53.3% [16], while in Belgium, national
guideline adherence in CAP was 25% on average [18].
In Hungary, fluoroquinolone became gradually the most
commonly used antibiotic class in adults with CAP with a
relative share exceeding 40% in 2011. In a comparable study,
similar trends have been reported in Belgium where it
increased from 10% to 30% between 2003 and 2010 [18].
Several factors have been listed as possible drivers of fluor-
oquinolone use such as once-daily dosing, activity against
CAP pathogens, concerns about resistance to standard thera-
pies and pharmaceutical advertising [15]. The increasing prev-
alence of macrolide and tetracycline resistance among
S. pneumoniae is often cited as ‘justifying reason’ for pre-
scribing fluoroquinolones [13]. This statement is slightly falla-
cious as tetracyclines and macrolides are primarily indicated
for the treatment of atypical organisms. The fact that the Hun-
garian guideline emphasizes the very low resistance rate of
S. pneumonia to fluoroquinolones [9] could also drive fluor-
oquinolone preference in Hungary.
It has been proven that quinolones are more prone to gener-
ate resistance compared with beta-lactams [20,21]. Increased
use of fluoroquinolones for outpatient respiratory infections
may lead to increased resistance rates among community-
acquired Gram-negative organisms [15]. Increased fluoroqui-
nolone resistance of Escherichia coli isolates in both urine and
non-urine samples have been reported recently [22]. Routine
prescribing of fluoroquinolones for CAP may limit the possi-
bility of therapeutic failure due to their proven efficacy for
both atypical and drug-resistant S. pneumonia, but may com-
promise the future effectiveness of this class of drugs. There-
fore, empirical usage of fluoroquinolones should be limited to
elderly patients and patients with comorbidities, while in
otherwise healthy patients with CAP, fluoroquinolones should
be used only in rare cases of true penicillin allergy or if initial
treatment fails.
In Hungary, aminopenicillins – a recommended agent by
the ESAC indicator and Hungarian guideline – were used
infrequently, while amoxicillin combined with clavulanic
acid (co-amoxiclav) was a popular agent. The high rate of
co-amoxiclav use could be partly explained by the fact that
– similarly to cefuroxime – national guidelines issued before
2006 recommended them as first-line agents in the empiric
therapy of immunocompetent adults with CAP. Secondly,
Table 2.
Relative use of antibacterials for the treatment of community-acquired
pneumonia in adults according to disease-specific quality indicators.
Years
ESAC quality indicator (QI)
QI 7b1 (acceptable range:
80–100%)
QI 7c2 (acceptable range:
0–5%)
Male Female Both Male Female Both
2007 6.0 6.9 6.4 26.5 24.8 25.6
2008 5.0 5.4 5.2 29.7 28.2 28.9
2009 5.1 5.7 5.4 31.5 30.0 30.7
2010 5.4 5.5 5.5 36.9 36.0 36.4
2011 4.6 5.1 4.9 41.1 39.7 40.4
1QI 7b: Percentage of adult patients with pneumonia receiving the
recommended antibacterials: J01CA penicillins with extended
spectrum and J01AA: tetracyclines.
2QI 7c: Percentage of adult patients with pneumonia receiving quino-
lone.
0% 20% 40% 60% 80% 100%
2007
2008
2009
2010
2011
Recommended antibacterials
Second line agent or agents recommended only in other patient group 
Non- recommended antibacterials 
Fig. 1. Antibiotic use in adults with community-acquired pneumonia according to the national guideline. White: Recommended antibacterials for
the empiric treatment of community-acquired pneumonia of adults (<65 years) without chronic diseases: macrolides, amoxicillin (min. 3 g daily)
and doxycycline. Grey: Second-line agent or agents recommended only in other patient groups (if comorbidity is present): amoxiclav, respiratory
quinolones. Black: Non-recommended antibacterials (for the empiric treatment of community-acquired pneumonia in adults (<65 years) without
chronic disease: penamecillin, penicillin V, ampicillin, cephalexin, cefaclor, sulphamethoxazole/trimethoprim, second-generation fluoroquinolones
(e.g. ciprofloxacin, ofloxacin, pefloxacin), third-generation oral cephalosporins (ceftibuten, cefixime).
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co-amoxiclav was marketed in Hungary earlier than amoxi-
cillin alone (co-amoxiclav: 1988; amoxicillin: 1991); hence,
doctors became familiar earlier with the combined agent.
Thirdly, in the general introduction of the Hungarian CAP
guideline, it is emphasized that Haemophilus influenzae and
Moraxella catarrhalis strains produce beta-lactamase in 5–
10% and 95%, respectively, and consequently therapy with
instable penicillins (e.g. amoxicillin) may fail. According to
data from the National Center for Epidemiology, S. pneumo-
niae strains were highly susceptible to ampicillin both in
2007 and in 2011 (88.4% and 97.6%) in outpatient samples.
Moreover, Moraxella catarrhalis – a frequent beta-lactamase
producing strain – is infrequently isolated in otherwise
healthy adults with CAP [9]. Lastly, the rate of beta-lactam-
ase producing Haemophilus influenzae strains might be
overestimated as samples derived from both ambulatory and
hospital care.
Therefore, in the light of previous and current national resis-
tance patterns, the use of high-dose amoxicillin in the empiric
treatment of healthy adults with CAP is justified, while the
use of its combination with clavulanic acid is superfluous.
In Hungary, macrolide use gradually decreased and
accounted for 19% of antibiotic use in 2011 in adults with
CAP. Although tetracyclines have been among the recom-
mended first-line agents in the empiric treatment of adults
with CAP both in national and in European guidelines, their
relative use was constantly around 4% in our study. However,
some decrease in the use of macrolides and tetracyclines in
Hungary is acceptable, given the fact that tetracycline or mac-
rolide-resistant S. pneumoniae is more prevalent. Nevertheless
their value in the treatment of atypical organism – which is a
frequent aetiologic agent in the studied aged group
(<65 years) – is unquestionable [23].
Our study had some limitations. The ESAC quality indica-
tors were defined for patients who should receive the recom-
mended antibacterial agent. Unfortunately, individual patient
data were not available for us; only aggregated antibiotic con-
sumption data linked to demography and indication. As the
prescribed DDD quantity of the different antibacterials used in
CAP did not differ considerably, the percentage of patients
treated and the relative use of prescribed antibiotics is compa-
rable. By the nature of the data source (aggregated data), we
could not assess the rate of mono or combination therapy,
could not differentiate initial and subsequent antibacterial ther-
apies and could not take into account comorbidities or drug
allergies. However, these limitations only affect results on
national guideline adherence and not the international quality
indicators.
Because of the inability to exclude patient with comorbidi-
ties (their general prevalence in the population was ~10%), the
Hungarian CAP guideline adherence was underestimated by
approximately 10% as use of more broad spectrum agents
(e.g. respiratory fluoroquinolone) is justified in these patients.
However, we believe this is an upper estimation of the limita-
tion as consumption data indirectly show (by the almost exclu-
sive use of oral antibacterials) that more severe and
progressive cases (including those with comorbidities) are
admitted to the hospital and not treated as outpatients. More-
over, we could calculate the additive sum of prevalence rate
of these chronic conditions (diabetes, chronic lower respiratory
diseases, etc.), while we did not control for disease overlap
(presence of several comorbidities).
In summary, our study identified some worrisome figures
and trends in the outpatient antibiotic treatment of adults with
CAP: extensive co-amoxiclav and fluoroquinolone use and
high rate of non-adherence to national and international
recommendations. We believe it is very highly unlikely
that guideline clarification and update alone will result in
rational antibacterial use patterns – incentives/regulations are
also warranted.
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